AstraZeneca has joined forces with UK-based Vodafone to provide mobile health (mHealth) services for improving health outcomes of patients with cardiovascular conditions.
The two partners will create mobile and internet-based services for patients to track and manage their conditions as part of their daily routine. The services are also aimed at improving medication adherence and giving patients’ confidence to manage their condition more effectively.
The services will be designed to work across geographies, with the ability to adapt to local variations in regulations and patient care.
AstraZeneca’s Intelligent Pharmaceutical Group will lead the project, with Vodafone providing technology, infrastructure and expertise for these services, as well as the ability to capture data from a variety of sources to improve overall engagement between patients and their health care professionals.
AstraZeneca Pharmaceutical Innovation vice-president Andy Jones said: "This work is an excellent example of collaboration between AstraZeneca and Vodafone.
"Together, we believe we are delivering something that will bring real benefit to patients in this important therapeutic area."
Health care professionals will be able to give patients the option to use these mHealth services, as an integral part of the patient care process, while patients will have access to personalised support, as well as coaching and treatment support to help manage their medication and lifestyle changes, and track their treatment progress.
Astra Zeneca has selected Vodafone based on its experience in delivering, and ability to scale, mHealth services.
Vodafone Machine to Machine director Erik Brenneis said bringing together connectivity with treatment and education will create effective outcomes for patients.
"AstraZeneca is a global leader in the mHealth field and we are delighted to work with them to develop these innovative services," Brenneis said.